Cargando…

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials

Rifapentine is a highly active antituberculosis antibiotic with treatment‐shortening potential; however, exposure–response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savic, RM, Weiner, M, MacKenzie, WR, Engle, M, Whitworth, WC, Johnson, JL, Nsubuga, P, Nahid, P, Nguyen, NV, Peloquin, CA, Dooley, KE, Dorman, SE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545752/ https://www.ncbi.nlm.nih.gov/pubmed/28124478 http://dx.doi.org/10.1002/cpt.634

Ejemplares similares

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure
por: Jayakumar, A., et al.
Publicado: (2016)

Longitudinal Model-Based Biomarker Analysis of Exposure-Response Relationships in Adults with Pulmonary Tuberculosis
por: Gewitz, Andrew D., et al.
Publicado: (2021)

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis
por: Conde, Marcus B., et al.
Publicado: (2016)

Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
por: Rosenthal, Ian M, et al.
Publicado: (2007)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk
por: Mkhize, Buyisile, et al.
Publicado: (2022)

Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention
por: Podany, Anthony T.
Publicado: (2020)

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
por: Sharan, Riti, et al.
Publicado: (2022)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice
por: Almeida, Deepak, et al.
Publicado: (2011)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis
por: Wu, Jun, et al.
Publicado: (2015)

Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques
Publicado: (2021)

Rifapentine-Proliposomes for Inhalation: In Vitro and In Vivo Toxicity
por: Patil-Gadhe, Arpana A., et al.
Publicado: (2014)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection
por: Huang, Hung-Ling, et al.
Publicado: (2020)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection
por: Holland, David P., et al.
Publicado: (2011)

A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
por: Francis, Jose, et al.
Publicado: (2019)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Rifapentine-linezolid-loaded PLGA microspheres for interventional therapy of cavitary pulmonary tuberculosis: preparation and in vitro characterization
por: Huang, Jieyun, et al.
Publicado: (2017)

Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
por: Masini, Tiziana, et al.
Publicado: (2022)

Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy( )
por: Huang, Hung Ling, et al.
Publicado: (2022)

Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial
por: Sigal, G.B., et al.
Publicado: (2017)

In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection
por: Albano, Mariana, et al.
Publicado: (2021)

Abnormal Dexamethasone Suppression Tests in a Rifapentine-Treated Patient With Primary Aldosteronism
por: Wang, Hongman, et al.
Publicado: (2020)

Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy
por: Magalhães, Joana, et al.
Publicado: (2020)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?
por: Zheng, Chunlan, et al.
Publicado: (2017)

Rifapentine Polylactic Acid Sustained-Release Microsphere Complex for Spinal Tuberculosis Therapy: Preparation, in vitro and in vivo Studies
por: Wang, Zhen, et al.
Publicado: (2021)

Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice
por: Liang, Qiuzhen, et al.
Publicado: (2020)

Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo
por: Qian, Xijing, et al.
Publicado: (2022)

Defining competency in flexible cystoscopy: a novel approach using cumulative Sum analysis
por: MacKenzie, Kenneth R., et al.
Publicado: (2016)

Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial
por: Semitala, Fred C., et al.
Publicado: (2021)

Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis — Colorado, 2011–2012
por: Bargman, Carolyn, et al.
Publicado: (2013)

Erratum to: Defining competency in flexible cystoscopy: a novel approach using cumulative Sum analysis
por: MacKenzie, Kenneth R., et al.
Publicado: (2016)

Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy
por: Chang, Yong S., et al.
Publicado: (2023)

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
por: Chang, Yong S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_huvtp9oaf35kapvc0lh04338um